Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):305-16

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS  RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather
 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):305-16

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist’s view

Davies A. J.

Cancer Research UK Medical Oncology Unit Department of Medical Oncology St Bartholomew’s Hospital, London, UK


PDF


Iodine [131I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells. The efficacy and safety of the non-myeloablative regimen has been demonstrated in follicular and transformed follicular lymphoma over the last decade in a series of clinical studies, culminating in FDA approval in June 2003. In patients with relapsed or refractory disease some remissions have proven to be durable, and frequently longer in duration than previously administered chemotherapeutic agents. As initial therapy for advanced stage follicular lymphoma, response rates are particularly impressive. Toxicity has been principally haematological, with a single nadir at 4-6 weeks post-therapy. Administration is free of many of the side effects of conventional chemotherapy, although concerns about the long term risk of therapy related myelodysplasia persist. The challenge now comes from deciding the correct place of iodine [131I] tositumomab in treatment algorithms for follicular and other ‘indolent’ lymphomas. Sequential administration after chemotherapy is being actively investigated, as is its role in myeloablative therapy. Issues of cost-benefit aside, it is a significant development in the therapy of these ‘chronic’ malignancies.

inizio pagina